Barinthus Biotherapeutics (BRNS) Equity Ratio (2020 - 2026)

Barinthus Biotherapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.72 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 11.48% year-over-year to 0.72; the trailing twelve-month figure through Mar 2026 stood at 0.72 (down 11.48% YoY), and the FY2025 full-year result was 0.76, down 6.87% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.72, down from 0.76 in the prior quarter.
• The five-year high for Equity Ratio was 0.9 in Q4 2022, with the low at 0.72 in Q1 2026.
• Historically, Equity Ratio has averaged 0.84 across 5 years, with a median of 0.85 in 2023.
• Annual changes were most pronounced in 2022 — Equity Ratio surged 378.81% — and 2026, when it dropped 11.48%.
• Barinthus Biotherapeutics' Equity Ratio stood at 0.9 in 2022, then declined by 3.15% to 0.87 in 2023, then declined by 6.89% to 0.81 in 2024, then retreated by 6.87% to 0.76 in 2025, then retreated by 4.67% to 0.72 in 2026.
• The last three Equity Ratio figures came in at 0.72 (Q1 2026), 0.76 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.